ARTICLE SUMMARY:
Glooko, which operates one of the largest remote patient monitoring platforms for the diabetes community, has a unique window on how the pandemic has altered patient care paradigms. In this Q&A, CEO Russ Johannesson shares his perspectives on the “systemic change” driving the adoption and acceptance of remote care and the lasting impact of this shift.
There’s little doubt that COVID-19 has profoundly impacted healthcare delivery and clinical research in the US, ushering in long overdue changes in regulations and reimbursement that have catalyzed what is likely to be a long-lasting movement toward more remote, patient-centric care. (See “COVID-19: A Pivotal Moment for Telemedicine and Remote Care Technologies,” MedTech Strategist, March 2020 and “Remote Patient Monitoring Enters a New Era,” MedTech Strategist, June 22, 2020.) The diabetes care community, with its well-established emphasis on remote monitoring and patient self-care, provides a particularly interesting perspective on these trends and on what the future might hold once the pandemic is relegated to the history books.
